

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	1,822,800	1,801,100	1,766,400	1,720,000
Prediabetes	496,200	506,400	511,500	498,800
Diagnosed diabetes	215,000	251,700	277,500	291,800
Undiagnosed diabetes	53,000	58,900	61,600	61,400
Total with diabetes (diagnosed and undiagnosed)	268,000	310,600	339,100	353,200
<b>Complications:</b>				
Visual impairment	35,300	40,100	42,900	43,800
Renal failure	510	580	620	620
Leg amputations	450	480	490	470
Annual deaths attributable to diabetes	2,320	2,590	2,710	2,700
Total annual cost (2015 dollars)	\$2.8 B	\$3.2 B	\$3.5 B	\$3.6 B
Annual medical costs	\$2.0 B	\$2.3 B	\$2.5 B	\$2.6 B
Annual nonmedical costs	\$0.8 B	\$0.9 B	\$1.0 B	\$1.0 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	329,800	372,000	408,500	426,400
Prediabetes	168,200	189,700	208,400	217,500
Diagnosed diabetes	62,300	70,300	77,200	80,600
Undiagnosed diabetes	23,100	26,000	28,600	29,900
Total with diabetes (diagnosed and undiagnosed)	85,400	96,400	105,800	110,400
<b>Complications:</b>				
Visual impairment	11,700	12,800	13,700	13,900
Renal failure	190	210	220	220
Leg amputations	140	150	150	150
Annual deaths attributable to diabetes	1,600	1,730	1,760	1,700
Total annual cost (2015 dollars)	\$1.1 B	\$1.2 B	\$1.4 B	\$1.4 B
Annual medical costs	\$1.0 B	\$1.1 B	\$1.3 B	\$1.3 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit [www.altfutures.org/diabetes2030](http://www.altfutures.org/diabetes2030).

Research funded by Novo Nordisk Inc.